Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging

AJR Am J Roentgenol. 2013 Oct;201(4):811-24. doi: 10.2214/AJR.12.10240.


Objective: The purposes of this article are to review the current management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) based on the 2012 National Comprehensive Cancer Network guidelines and to describe the role of imaging in a multidisciplinary approach.

Conclusion: The management of GEP-NETs has become complex, requiring a multidisciplinary approach. The World Health Organization classification of GEP-NETs has been revised; the U.S. Food and Drug Administration has approved molecular targeted agents (sunitinib, everolimus) for the treatment of pancreatic NETs; and the National Comprehensive Cancer Network clinical practice guidelines have been updated.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Diagnostic Imaging / methods*
  • Diagnostic Imaging / standards
  • Female
  • Gastrointestinal Neoplasms / diagnosis*
  • Gastrointestinal Neoplasms / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Molecular Targeted Therapy / standards
  • Molecular Targeted Therapy / trends
  • Neuroendocrine Tumors / diagnosis*
  • Neuroendocrine Tumors / drug therapy*
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / drug therapy*
  • Practice Guidelines as Topic
  • Treatment Outcome